Patents by Inventor Per-Mikael Aberg

Per-Mikael Aberg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230347316
    Abstract: The present invention relates to a chromatography ligand, which comprises Domain C from Staphylococcus protein A (SpA), or a functional fragment or variant thereof. The chromatography ligand presents an advantageous capability of withstanding harsh cleaning in place (CIP) conditions, and is capable of binding Fab fragments of antibodies. The ligand may be provided with a terminal coupling group, such as arginine or cysteine, to facilitate its coupling to an insoluble carrier such as beads or a membrane. The invention also relates to a process of using the ligand in isolation of antibodies, and to a purification protocol which may include washing steps and/or regeneration with alkali.
    Type: Application
    Filed: November 4, 2022
    Publication date: November 2, 2023
    Inventors: Martin HALL, Sture LARSSON, Andreas MURANYI, Gustav RODRIGO, Jinyu ZOU, Per-Mikael ABERG
  • Patent number: 11517879
    Abstract: The present invention relates to a chromatography ligand, which comprises Domain C from Staphylococcus protein A (SpA), or a functional fragment or variant thereof. The chromatography ligand presents an advantageous capability of withstanding harsh cleaning in place (CIF) conditions, and is capable of binding Fab fragments of antibodies. The ligand may be provided with a terminal coupling group, such as arginine or cysteine, to facilitate its coupling to an insoluble carrier such as beads or a membrane. The invention also relates process of using the ligand in isolation of antibodies, and to a purification protocol which may include washing steps and/or regeneration with alkali.
    Type: Grant
    Filed: November 30, 2020
    Date of Patent: December 6, 2022
    Assignee: CYTIVA BIOPROCESS R&D AB
    Inventors: Martin Hall, Sture Larsson, Andreas Muranyi, Gustav Rodrigo, Jinyu Zou, Per-Mikael Aberg
  • Publication number: 20210291143
    Abstract: The present invention relates to a chromatography ligand, which comprises Domain C from Staphylococcus protein A (SpA), or a functional fragment or variant thereof. The chromatography ligand presents an advantageous capability of withstanding harsh cleaning in place (CIF) conditions, and is capable of binding Fab fragments of antibodies. The ligand may be provided with a terminal coupling group, such as arginine or cysteine, to facilitate its coupling to an insoluble carrier such as beads or a membrane. The invention also relates process of using the ligand in isolation of antibodies, and to a purification protocol which may include washing steps and/or regeneration with alkali.
    Type: Application
    Filed: November 30, 2020
    Publication date: September 23, 2021
    Inventors: Martin HALL, Sture LARSSON, Andreas MURANYI, Gustav RODRIGO, Jinyu ZOU, Per-Mikael ABERG
  • Patent number: 10875007
    Abstract: The present invention relates to a chromatography ligand, which comprises Domain C from Staphylococcus protein A (SpA), or a functional fragment or variant thereof. The chromatography ligand presents an advantageous capability of withstanding harsh cleaning in place (CIP) conditions, and is capable of binding Fab fragments of antibodies. The ligand may be provided with a terminal coupling group, such as arginine or cysteine, to facilitate its coupling to an insoluble carrier such as beads or a membrane. The invention also relates to a process of using the ligand in isolation of antibodies, and to a purification protocol which may include washing steps and/or regeneration with alkali.
    Type: Grant
    Filed: June 17, 2019
    Date of Patent: December 29, 2020
    Assignee: CYTIVA BIOPROCESS R&D AB
    Inventors: Martin Hall, Sture Larsson, Andreas Muranyi, Gustav Rodrigo, Jinyu Zou, Per-Mikael Aberg
  • Publication number: 20190308168
    Abstract: The present invention relates to a chromatography ligand, which comprises Domain C from Staphylococcus protein A (SpA), or a functional fragment or variant thereof. The chromatography ligand presents an advantageous capability of withstanding harsh cleaning in place (CIP) conditions, and is capable of binding Fab fragments of antibodies. The ligand may be provided with a terminal coupling group, such as arginine or cysteine, to facilitate its coupling to an insoluble carrier such as beads or a membrane. The invention also relates to a process of using the ligand in isolation of antibodies, and to a purification protocol which may include washing steps and/or regeneration with alkali.
    Type: Application
    Filed: June 17, 2019
    Publication date: October 10, 2019
    Inventors: Martin HALL, Sture LARSSON, Andreas MURANYI, Gustav RODRIGO, Jinyu ZOU, Per-Mikael ABERG
  • Patent number: 10343142
    Abstract: The present invention relates to a chromatography ligand, which comprises Domain C from Staphylococcus protein A (SpA), or a functional fragment or variant thereof. The chromatography ligand presents an advantageous capability of withstanding harsh cleaning in place (CIP) conditions, and is capable of binding Fab fragments of antibodies. The ligand may be provided with a terminal coupling group, such as arginine or cysteine, to facilitate its coupling to an insoluble carrier such as beads or a membrane. The invention also relates process of using the ligand in isolation of antibodies, and to a purification protocol which may include washing steps and/or regeneration with alkali.
    Type: Grant
    Filed: November 13, 2018
    Date of Patent: July 9, 2019
    Assignee: GE HEALTHCARE BIOPROCESS R&D AB
    Inventors: Martin Hall, Sture Larsson, Andreas Muranyi, Gustav Rodrigo, Jinyu Zou, Per-Mikael Aberg
  • Publication number: 20190060869
    Abstract: The present invention relates to a chromatography ligand, which comprises Domain C from Staphylococcus protein A (SpA), or a functional fragment or variant thereof. The chromatography ligand presents an advantageous capability of withstanding harsh cleaning in place (CIP) conditions, and is capable of binding Fab fragments of antibodies. The ligand may be provided with a terminal coupling group, such as arginine or cysteine, to facilitate its coupling to an insoluble carrier such as beads or a membrane. The invention also relates process of using the ligand in isolation of antibodies, and to a purification protocol which may include washing steps and/or regeneration with alkali.
    Type: Application
    Filed: November 13, 2018
    Publication date: February 28, 2019
    Applicant: GE Healthcare BioProcess R&D AB
    Inventors: Martin Hall, Sture Larsson, Andreas Muranyi, Gustav Rodrigo, Jinyu Zou, Per-Mikael Aberg
  • Patent number: 10213765
    Abstract: The present invention relates to a chromatography ligand, which comprises Domain C from Staphylococcus protein A (SpA), or a functional fragment or variant thereof. The chromatography ligand presents an advantageous capability of withstanding harsh cleaning in place (CIP) conditions, and is capable of binding Fab fragments of antibodies. The ligand may be provided with a terminal coupling group, such as arginine or cysteine, to facilitate its coupling to an insoluble carrier such as beads or a membrane. The invention also relates to a process of using the ligand in isolation of antibodies, and to a purification protocol which may include washing steps and/or regeneration with alkali.
    Type: Grant
    Filed: May 23, 2017
    Date of Patent: February 26, 2019
    Assignee: GE Healthcare Bioprocess R&D
    Inventors: Martin Hall, Sture Larsson, Andreas Muranyi, Gustav Rodrigo, Jinyu Zou, Per-Mikael Aberg
  • Patent number: 10189891
    Abstract: The invention discloses an immunoglobulin-binding protein comprising one or more mutated immunoglobulin-binding domains (monomers) of staphylococcal Protein A (E, D, A, B, C) or protein Z or a functional variant thereof, wherein in at least one of the one or more mutated monomers, the asparagine or histidine at the position corresponding to H18 of the B domain of Protein A or of Protein Z has been deleted or substituted with a first amino acid residue which is not proline or asparagine and wherein, if the amino acid residue at position 57 is proline and the amino acid residue at position 28 is asparagine, then the amino acid residue at the position corresponding to H18 of the B domain of protein A or of protein Z is not serine, threonine or lysine.
    Type: Grant
    Filed: March 26, 2013
    Date of Patent: January 29, 2019
    Assignee: GE Healthcare BioProcess R&D AB
    Inventors: Mats Ander, Goran Bauren, Tomas Bjorkman, Per-Mikael Aberg, Gustav Rodrigo
  • Publication number: 20170259244
    Abstract: The present invention relates to a chromatography ligand, which comprises Domain C from Staphylococcus protein A (SpA), or a functional fragment or variant thereof. The chromatography ligand presents an advantageous capability of withstanding harsh cleaning in place (CIF) conditions, and is capable of binding Fab fragments of antibodies. The ligand may be provided with a terminal coupling group, such as arginine or cysteine, to facilitate its coupling to an insoluble carrier such as beads or a membrane. The invention also relates process of using the ligand in isolation of antibodies, and to a purification protocol which may include washing steps and/or regeneration with alkali.
    Type: Application
    Filed: May 23, 2017
    Publication date: September 14, 2017
    Applicant: GE Healthcare BioProcess R&D AB
    Inventors: Martin Hall, Sture Larsson, Andreas Muranyi, Gustav Rodrigo, Jinyu Zou, Per-Mikael Aberg
  • Patent number: 9663559
    Abstract: The present invention relates to a chromatography ligand, which comprises Domain C from Staphylococcus protein A (SpA), or a functional fragment or variant thereof. The chromatography ligand presents an advantageous capability of withstanding harsh cleaning in place (CIP) conditions, and is capable of binding Fab fragments of antibodies. The ligand may be provided with a terminal coupling group, such as arginine or cysteine, to facilitate its coupling to an insoluble carrier such as beads or a membrane. The invention also relates to a process of using the ligand in isolation of antibodies, and to a purification protocol which may include washing steps and/or regeneration with alkali.
    Type: Grant
    Filed: March 7, 2016
    Date of Patent: May 30, 2017
    Assignee: GE Healthcare Bio-Sciences AB
    Inventors: Martin Hall, Sture Larsson, Andreas Muranyi, Gustav Rodrigo, Jinyu Zou, Per-Mikael Aberg
  • Publication number: 20160200797
    Abstract: The present invention relates to a chromatography ligand, which comprises Domain C from Staphylococcus protein A (SpA), or a functional fragment or variant thereof. The chromatography ligand presents an advantageous capability of withstanding harsh cleaning in place (CIP) conditions, and is capable of binding Fab fragments of antibodies. The ligand may be provided with a terminal coupling group, such as arginine or cysteine, to facilitate its coupling to an insoluble carrier such as beads or a membrane. The invention also relates to a process of using the ligand in isolation of antibodies, and to a purification protocol which may include washing steps and/or regeneration with alkali.
    Type: Application
    Filed: March 7, 2016
    Publication date: July 14, 2016
    Inventors: Martin Hall, Sture Larsson, Andreas Muranyi, Gustav Rodrigo, Jinyu Zou, Per-Mikael Aberg
  • Patent number: 9290549
    Abstract: The present invention relates to a chromatography ligand, which comprises Domain C from Staphylococcus protein A (SpA), or a functional fragment or variant thereof. The chromatography ligand presents an advantageous capability of withstanding harsh cleaning in place (CIP) conditions, and is capable of binding Fab fragments of antibodies. The ligand may be provided with a terminal coupling group, such as arginine or cysteine, to facilitate its coupling to an insoluble carrier such as beads or a membrane. The invention also relates to a process of using the ligand in isolation of antibodies, and to a purification protocol which may include washing steps and/or regeneration with alkali.
    Type: Grant
    Filed: January 27, 2014
    Date of Patent: March 22, 2016
    Assignee: GE Healthcare Bio-Sciences AB
    Inventors: Martin Hall, Sture Larsson, Andreas Muranyi, Gustav Rodrigo, Jinyu Zou, Per-Mikael Aberg
  • Patent number: 9187555
    Abstract: The present invention relates to a method of separating one or more immunoglobulin containing proteins from a liquid. The method includes first contacting the liquid with a separation matrix comprising ligands immobilized to a support; allowing the immunoglobulin containing proteins to adsorb to the matrix by interaction with the ligands; followed by an optional step of washing the matrix containing the immunoglobulin containing proteins adsorbed thereon; and recovering said immunoglobulin containing proteins by contacting the matrix with an eluent which releases the proteins.
    Type: Grant
    Filed: December 19, 2011
    Date of Patent: November 17, 2015
    Assignee: GE Healthcare Bio-Sciences AB
    Inventors: Tomas Bjorkman, Bjorn Noren, Gustav Rodrigo, Jelena Vasic, Per-Mikael Aberg
  • Publication number: 20150080554
    Abstract: The invention discloses an immunoglobulin-binding protein comprising one or more mutated immunoglobulin-binding domains (monomers) of staphylococcal Protein A (E, D, A, B, C) or protein Z or a functional variant thereof, wherein in at least one of the one or more mutated monomers, the asparagine or histidine at the position corresponding to H18 of the B domain of Protein A or of Protein Z has been deleted or substituted with a first amino acid residue which is not proline or asparagine and wherein, if the amino acid residue at position 57 is proline and the amino acid residue at position 28 is asparagine, then the amino acid residue at the position corresponding to H18 of the B domain of protein A or of protein Z is not serine, threonine or lysine.
    Type: Application
    Filed: March 26, 2013
    Publication date: March 19, 2015
    Applicant: GE HEALTHCARE BIO-SCIENCES AB
    Inventors: Mats Ander, Goran Bauren, Tomas Bjorkman, Per-Mikael Aberg, Gustav Rodrigo
  • Patent number: 8772447
    Abstract: The present invention relates to a chromatography ligand, which comprises Domain C from Staphylococcus protein A (SpA), or a functional fragment or variant thereof. The chromatography ligand presents an advantageous capability of withstanding harsh cleaning in place (CIP) conditions, and is capable of binding Fab fragments of antibodies. The ligand may be provided with a terminal coupling group, such as arginine or cysteine, to facilitate its coupling to an insoluble carrier such as beads or a membrane. The invention also relates to a process of using the ligand in isolation of antibodies, and to a purification protocol which may include washing steps and/or regeneration with alkali.
    Type: Grant
    Filed: July 27, 2012
    Date of Patent: July 8, 2014
    Assignee: GE Healthcare Bio-Sciences AB
    Inventors: Martin Hall, Sture Larsson, Andreas Muranyi, Gustav Rodrigo, Jinyu Zou, Per-Mikael Aberg
  • Patent number: 8728828
    Abstract: The present invention relates to a separation matrix comprised of porous particles to which antibody-binding protein ligands have been immobilized, wherein the ligand density is in the range of 5.0-10 mg/ml; the gel phase distribution coefficient of the particles expressed as Kav for a dextran of size 110 kDa is above 0.65 and the median particle diameter is between 65-84 ?m. The carbohydrate material is preferably highly cross-linked agarose.
    Type: Grant
    Filed: December 22, 2005
    Date of Patent: May 20, 2014
    Assignee: GE Healthcare Bio-Sciences AB
    Inventors: Hans Berg, Hans Johansson, Gunnar Malmquist, Per-Mikael Aberg
  • Publication number: 20140135476
    Abstract: The present invention relates to a chromatography ligand, which comprises Domain C from Staphylococcus protein A (SpA), or a functional fragment or variant thereof. The chromatography ligand presents an advantageous capability of withstanding harsh cleaning in place (CIP) conditions, and is capable of binding Fab fragments of antibodies. The ligand may be provided with a terminal coupling group, such as arginine or cysteine, to facilitate its coupling to an insoluble carrier such as beads or a membrane. The invention also relates to a process of using the ligand in isolation of antibodies, and to a purification protocol which may include washing steps and/or regeneration with alkali.
    Type: Application
    Filed: January 27, 2014
    Publication date: May 15, 2014
    Applicant: GE HEALTHCARE BIO-SCIENCES AB
    Inventors: MARTIN HALL, STURE LARSSON, ANDREAS MURANYI, GUSTAV RODRIGO, JINYU ZOU, PER-MIKAEL ABERG
  • Publication number: 20130338339
    Abstract: The present invention relates to a method of separating one or more immunoglobulin containing proteins from a liquid. The method includes first contacting the liquid with a separation matrix comprising ligands immobilised to a support; allowing the immunoglobulin containing proteins to adsorb to the matrix by interaction with the ligands; followed by an optional step of washing the matrix containing the immunoglobulin containing proteins adsorbed thereon; and recovering said immunoglobulin containing proteins by contacting the matrix with an eluent which releases the proteins.
    Type: Application
    Filed: December 19, 2011
    Publication date: December 19, 2013
    Applicant: GE HEALTHCARE BIO-SCIENCES AB
    Inventors: Tomas Bjorkman, Bjorn Noren, Gustav Rodrigo, Jelena Vasic, Per-Mikael Aberg
  • Patent number: 8329860
    Abstract: The present invention relates to a chromatography ligand, which comprises Domain C from Staphylococcus protein A (SpA), or a functional fragment or variant thereof. The chromatography ligand presents an advantageous capability of withstanding harsh cleaning in place (CIP) conditions, and is capable of binding Fab fragments of antibodies. The ligand may be provided with a terminal coupling group, such as arginine or cysteine, to facilitate its coupling to an insoluble carrier such as beads or a membrane. The invention also relates to a process of using the ligand in isolation of antibodies, and to a purification protocol which may include washing steps and/or regeneration with alkali.
    Type: Grant
    Filed: September 27, 2007
    Date of Patent: December 11, 2012
    Assignee: GE Healthcare Bio-Sciences AB
    Inventors: Martin Hall, Sture Larsson, Andreas Muranyi, Gustav Rodrigo, Jinyu Zou, Per-Mikael Aberg